



(51) International Patent Classification:

C07D 401/14 (2006.01) C07D 405/04 (2006.01)
 C07D 413/14 (2006.01) C07D 409/04 (2006.01)
 C07D 231/54 (2006.01) C07D 413/04 (2006.01)
 C07D 401/04 (2006.01) C07D 413/10 (2006.01)
 C07D 235/02 (2006.01) C07D 417/04 (2006.01)
 C07D 401/10 (2006.01) A61P 29/00 (2006.01)
 C07D 403/04 (2006.01) A61K 31/416 (2006.01)
 C07D 403/10 (2006.01) A61K 31/4184 (2006.01)

(21) International Application Number:

PCT/US2019/037543

(22) International Filing Date:

17 June 2019 (17.06.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/685,742 15 June 2018 (15.06.2018) US
 62/687,602 20 June 2018 (20.06.2018) US

(71) Applicant: **REATA PHARMACEUTICALS, INC.**
 [US/US]; 2801 Gateway Drive, Suite 150, Irving, TX
 75063-2648 (US).

(72) Inventors: **JIANG, Xin**; c/o Reata Pharmaceuticals, Inc.,
 2801 Gateway Drive, Suite 150, Irving, TX 75063-2648
 (US). **VISNICK, Melean**; c/o Reata Pharmaceuticals, Inc.,
 2801 Gateway Drive, Suite 150, Irving, TX 75063-2648
 (US). **BENDER, Christopher, F.**; c/o Reata Pharmaceu-
 ticals, Inc., 2801 Gateway Drive, Suite 150, Irving, TX
 75063-2648 (US). **BOLTON, Gary**; c/o Reata Pharmaceu-
 ticals, Inc., 2801 Gateway Drive, Suite 150, Irving, TX
 75063-2648 (US). **CAPRATHE, Bradley**; c/o Reata Phar-
 maceuticals, Inc., 2801 Gateway Drive, Suite 150, Irving,
 TX 75063-2648 (US). **LEE, Chitase**; c/o Reata Pharma-
 ceuticals, Inc., 2801 Gateway Drive, Suite 150, Irving, TX
 75063-2648 (US). **KORNBERG, Brian**; c/o Reata Phar-
 maceuticals, Inc., 2801 Gateway Drive, Suite 150, Irving,

TX 75063-2648 (US). **O'BRIEN, Patrick**; c/o Reata Phar-
 maceuticals, Inc., 2801 Gateway Drive, Suite 150, Irving,
 TX 75063-2648 (US). **HOTEMA, Martha, R.**; c/o Reata
 Pharmaceuticals, Inc., 2801 Gateway Drive, Suite 150, Ir-
 ving, TX 75063-2648 (US).

(74) Agent: **LONG, S., Reid**; Parker Highlander PLLC, 1120
 So. Capital of Texas Highway, Bldg. One Suite 200, Austin,
 TX 78746 (US).


(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
 HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
 KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
 KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORγ



(1)

(57) Abstract: Disclosed herein are compounds of the formula: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to modulate the activity of IL-17 and RORγ. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or for autoimmune disorders.